Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Modified IP Regimen for Ovarian Cancer Leads to 90% Completion Rate

July 18th 2012

A modified intraperitoneal (IP) regimen for advanced ovarian cancer demonstrated feasibility, tolerability, and evidence of effectiveness, results of a small pilot study suggest.

Close Call for Cost-Effectiveness of Bevacizumab in Ovarian Cancer

July 9th 2012

Recent clinical and economic studies have suggested that ovarian cancer regimens containing bevacizumab could fall within the boundaries of cost-effectiveness, at least for some patients.

Paclitaxel Shortage May Add Millions to Cost of Ovarian Cancer Care

June 27th 2012

A chronic shortage of the most commonly used taxane for ovarian cancer would add almost $9 million a month to the cost of care if half of newly diagnosed cases were affected.

Dr. Pujade-Lauraine on the AURELIA Bevacizumab Trial

June 2nd 2012

Dr. Eric Pujade-Lauraine, from UniversitÃ© de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.

Avastin Delays Disease Progression in Platinum-Resistant Ovarian Cancer

June 2nd 2012

Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.

Dr. Davidson on Screening for Ovarian Cancer

May 23rd 2012

Dr. Nancy Davidson, from the University of Pittsburgh Cancer Institute, on Screening for Ovarian Cancer

Hereditary Breast and Ovarian Cancer: Which Patients Are at High Risk?

May 23rd 2012

Detecting hereditary cancer and providing genetic counseling can help prevent a new primary cancer and may also help to protect family members from developing cancer.

NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 23rd 2012

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Genetic Assessment of Breast and Ovarian Cancer Risk

April 30th 2012

Understanding the genetic basis of breast and ovarian cancers is essential to providing patients with effective preventive and/or management strategies that can improve outcomes.

PARP Inhibitors Intriguing Despite Research Setbacks

April 26th 2012

Despite initial disappointing findings on overall survival, PARP inhibitors remains under active investigation for patients with ovarian cancer.

Supreme Court Asks for Reconsideration on BRCA1 and BRCA2 Patents

March 27th 2012

The US Supreme Court has asked an appellate court to reconsider its decision regarding patents held on two genes.

Improved Survival in Women With Invasive Epithelial Ovarian Cancer and Germline BRCA Gene Mutations

March 26th 2012

Researchers are reporting better survival rates in women with invasive EOC and germline mutations in the tumor suppressor genes BRCA1 and BRCA2 than in patients who are noncarriers.

Dr. Birrer on the Ovarian Cancer Avastin OS Benefit

March 2nd 2012

Dr. Michael Birrer from Massachusetts General Hospital Cancer Center on the Ovarian Cancer Avastin OS Benefit

Benefits of Bevacizumab in Ovarian Cancer Clarified

March 1st 2012

Bevacizumab has failed to demonstrate statistically significant improvements in OS for women with recurrent ovarian cancer in 2 recent clinical trials.

Bevacizumab Delivers Ovarian Cancer Benefit But Not OS Upgrade

February 22nd 2012

Bevacizumab improved progression-free survival in patients with ovarian cancer but was not shown to affect overall survival.

Dr. Birrer Discusses the GOG0218 and ICON7 Trials

February 2nd 2012

Dr. Michael Birrer, from Massachusetts General Hospital Cancer Center, Discusses the GOG0218 and ICON7 Trials

BRCA1 and BRCA2 Mutations Yield Better Prognosis in Ovarian Cancer Patients

January 25th 2012

Patients with ovarian cancer who express BRCA1/2 mutations demonstrated a better overall survival after 5 years.

Dr. Birrer Discusses Recurrent Ovarian Cancer Treatment

January 23rd 2012

Dr. Michael Birrer, from Massaschusetts General Hospital Cancer Center, Discusses Recurrent Ovarian Cancer Treatment

Brain Metastasis Common in Ovarian Cancer

January 20th 2012

Half of all women with advanced ovarian cancer who develop brain cancer have a single metastasis to the brain.

Fertility Treatment Increases Risk of Ovarian Cancer

January 16th 2012

Subfertile women who undergo ovarian stimulation for in vitro fertilization have an increased risk of ovarian malignancies.